Last close · 16 Oct 2026
Rs 41.37 -0.22%
Valuation · at the close on 16 Oct 2026
IBL HealthCare Limited (IBLHL) valuation
At Rs 41.37 (close on 16 Oct 2026) IBLHL trades at 18.5× earnings (FY2026), below its five-year average of 99.3× and above the Pharmaceuticals median of 12.3×.
- P/E · today
- 18.5×
- FY2026
- 5-yr average99.3× Sector median12.3×
- P/B · today
- —
- FY2026
- 5-yr average— Sector median3.03×
- EV/EBITDA · today
- —
- 5-yr average— Sector median6.6×
- Dividend yield · today
- —
- FY2026
- 5-yr average— Payers' median4.7%
Market value — at Rs 41.37. Sector medians use the latest close of 14 Pharmaceuticals companies; P/E and P/B only where earnings / book value are positive; the yield median covers dividend payers only. Not investment advice.
Valuation history
At each fiscal year-end price.
| Rs bn | FY2026 Jul 2025 – Jun 2026 | FY2025 Jul 2024 – Jun 2025 | FY2024 Jul 2023 – Jun 2024 | FY2023 Jul 2022 – Jun 2023 | FY2022 Jul 2021 – Jun 2022 |
|---|---|---|---|---|---|
| Market capitalisation | 5.2 | 53.6 | 2.6 | 2.3 | 3.4 |
| Enterprise value | 4.5 | 53.6 | 2.3 | 2.5 | 3.5 |
| Share price (period end) Rs | 53.02 | 54.43 | 26.88 | 23.59 | 34.25 |
| P/E (diluted) | — | 25.76× | 350.52× | 7.52× | 13.37× |
| Price to book | — | 2.31× | 1.25× | 1.10× | 2.17× |
| Price to sales | — | 1.24× | 0.73× | 0.58× | 1.11× |
| EV / EBITDA | — | 118.33× | 15.24× | 3.95× | 5.98× |
| EV / Sales | 0.98× | 12.40× | 0.64× | 0.63× | 0.97× |
| Dividend yield (gross) | — | 0.0% | 0.0% | 3.1% | 1.6% |
| Free cash flow yield | — | (5.2%) | 21.4% | 1.0% | 1.4% |
| PEG ratio | — | 0.01× | (3.59×) | 0.33× | (0.84×) |
| P/E (diluted, normalised) | — | 25.76× | 350.52× | 7.52× | 13.34× |
| Price to book — 5-year average | — | 2.03× | 2.10× | 2.23× | 2.80× |
| EV / EBITDA — 5-year average | — | 29.85× | 8.63× | 8.26× | 11.14× |
| Dividend yield — 5-year average | — | 1.2% | 1.6% | 1.9% | 1.6% |
IBLHL valuation: frequently asked questions
What is IBLHL's P/E ratio?
At the closing price of Rs 41.37 on 16 Oct 2026, IBLHL trades at a P/E of 18.5× based on EPS of Rs 2.24 (FY2026).
Information only, not investment advice.